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A new study shows how a single cytokine, interleukin-4,
regulates hematopoietic lineage choice by activating the
JAK3–STAT6 pathway, which causes dendritic-cell-specific
DNA demethylation.addition of granulocyte-macrophage colony-stimulatingDNA methylation is essential for normal development
and cellular homeostasis. Aberrant DNA methylation
has been implicated in several cancers and developmen-
tal diseases. To elucidate how aberrant DNA methyla-
tion patterns contribute to the development of different
diseases, it is essential to understand how the DNA methy-
lation machinery regulates the differentiation of normal
cells. A new study in Genome Biology by Vento-Tormo
and colleagues demonstrates how external signals influ-
ence epigenetic regulation and cell differentiation [1].Interleukin-4 discriminates between two
cell-differentiation pathways and induces dendritic
cell-specific DNA demethylation
Hematopoiesis is the formation of blood cells, and one
of the most extensively characterized differentiation sys-
tems, in which hematopoietic stem cells (HSCs) commit
to either the lymphoid lineage (and become lympho-
cytes) or the myeloid lineage (where they can differenti-
ate into cell types including erythrocytes, granulocytes
and monocytes). As these cells are short lived and do
not self-renew, there needs to be a steady turnover of
new blood cells and the maintenance of an HSC pool.
The DNA methylation patterns at promoters and en-
hancers in different myeloid cell types regulate cell-
specific transcriptional activity and thereby contribute
to cell identity. However, it is not known how the cell-
specific DNA methylation pattern is established. This
knowledge is essential to be able to understand howCorrespondence: andreas.lennartsson@ki.se
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to the development of acute myeloid leukemia (AML).
In this new study, Vento-Tormo and colleagues use
interleukin-4 (IL-4) to discriminate between the pathways
by which human monocytes differentiate into macro-
phages or dendritic cells (DCs) [1]. They show that the
factor (GM-CSF) alone causes differentiation of human
monocytes into macrophages, whereas GM-SCF and IL-4
in combination lead to differentiation into DCs. The au-
thors show that IL-4 binds to the IL-4 receptor and acti-
vates the tyrosine-protein kinase JAK3–STAT6 pathway,
which provides a simple membrane-to-nucleus mechan-
ism for rapidly inducing gene expression. This causes acti-
vation of the methylcytosine dioxygenase TET2, which
has an important regulatory role in the production of
blood cells from HSCs and downstream TET2-dependent
DC-specific DNA demethylation and gene expression pro-
file. The activation of the signal transducer and activator
of transcription STAT6 is probably the key regulator of
this process as IL-4 can be bypassed by using constitu-
tively active STAT6 [1].TET2 has an important role in myeloid
differentiation
An important role for TET2 in late monocytic differenti-
ation has previously been suggested by the authors and
by other groups [2]. The entire TET gene family can
oxidize methylated cytosine to hydroxymethylated cyto-
sine; however, it is likely that they have partial and non-
overlapping target specificities. It has been suggested
that TET2 has a stronger effect on enhancer regions
than TET1, based on data from mouse embryonic stem
cells (ESCs) [3]. TET2 might consequently play an im-
portant role in regulating enhancer activity. Indeed,
Vento-Tormo and colleagues show that the sites that are
demethylated during differentiation to DCs or macro-
phages are enriched in enhancer regions and are specific
for the process [1].
IL-4-induced DNA demethylation, which is mediated
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and the downregulation of TET2 inhibits both DC and
macrophage differentiation as a result of altered
demethylation.
TET2-mediated demethylation of DNA is also import-
ant for the regulation of HSC proliferation and early
lineage choice [4]. TET2-deficient HSCs display reduced
DNA hydroxymethylation levels and increased self-
renewal. This causes an enlarged HSC and progenitor cell
pool owing to increased cell division and self-renewal.
Consequently, both the lymphoid and myeloid lineages
expand, but with a bias towards the myeloid lineage and
development of various myeloid malignancies. However,
TET2 loss-of-function mutations have been observed in
both myeloid as well as lymphoid leukemia.
The key role of TET2 in myeloid differentiation is sup-
ported by the loss of Tet2 in an AML mouse model, where
it has been shown to result in enhancer hypermethylation.
By contrast, hypermethylation was not observed at pro-
moters [5]. These results suggest that TET2 is essential to
keep enhancers hypomethylated, which thereby protects
the cells from leukemic transformation [5]. TET2 muta-
tions in AML might therefore disturb the myeloid differ-
entiation program by causing aberrant enhancer activity.
DNA methylation patterns and cell identity
DNA methylation patterns change during cellular differ-
entiation, which locks the transcriptional state according
to the specific cell type. This process occurs at all stages
of development, from embryogenesis to adult stem cell
differentiation. In a DNA-methylation analysis compar-
ing brain, liver, ESCs and 19 blood and skin cell samples
at different stages of maturation, it was shown that each
cell type can be distinguished based on its DNA methy-
lation pattern [6]. This analysis shows that different cell
types are defined by unique DNA methylation patterns.
Vento-Tormo and colleagues found that the main
changes in DNA methylation occur during differenti-
ation, and only very few changes take place when DCs
or macrophages become activated with bacteria-derived
lipopolysaccharide (LPS). By contrast, thousands of
genes change expression in both the differentiation and
activation processes [1]. This suggests that, when the cell
identity is established, only minor changes in DNA
methylation occur. This is in agreement with DNA
methylation as a mechanism for a cell to “remember” its
identity and transcriptional program during develop-
ment. This has previously also been shown in another
myeloid lineage, the neutrophil lineage. In neutrophil
differentiation, DNA demethylation predominantly oc-
curs before the pro-myelocytic stage of differentiation
[7]. At this stage, all lineage choices are made and the
cell fate established, and therefore no changes in DNA
methylation are required.DNA methylation represses transcription through ei-
ther active transcriptional silencing or by inhibiting tran-
scriptional activation, depending on the precise genomic
location and context of the methylated cytosines. The
majority of cytosines that are methylated during differ-
entiation are already transcriptionally silent in ESCs [8],
suggesting that silencing precedes DNA methylation. In
a similar, but opposite, manner, Vento-Tormo and col-
leagues show that several genes demethylated during DC
or macrophage differentiation are not expressed until
the macrophage becomes activated by LPS. Hence, DNA
demethylation might not directly regulate transcription,
but instead creates a permissive chromatin state that can
be activated upon stimulation.
Interestingly, IL-4 signaling not only induces DC-specific
DNA demethylation but it also prevents demethylation of
cytosines during macrophage differentiation [1]. A similar
mechanism has been described in lymphoid differenti-
ation, where lymphoid progenitors have enhanced methy-
lation at binding sites of myeloid transcription factors [6].
The increased methylation might inhibit the binding of
these factors and block myeloid differentiation in lymph-
oid cells, in a manner similar to that of the IL-4-induced
inhibition of demethylation at macrophage-specific sites.
Therefore, DNA methylation defines cell identity by
allowing one cell identity, while blocking the other.
Aberrant DNA methylation in diseases
Epigenetic alterations can occur either before, or as a
consequence of, somatic mutations. Somatic mutations
in the DNA methylation machinery are documented in
several cancers. In acute myeloid leukemia (AML),
mutations in DNA methylation regulators such as
DNMT3A, TET2, IDH1 and IDH2 are frequent, and
loss of function of TET2 and DNMT3A are early events
in leukemogenesis [9].
By contrast, cases of aberrant epigenetic landscapes
that do not have co-current somatic mutations have
proven difficult to find. However, childhood brain tu-
mors, ependymomas, display the CpG island methylator
phenotype (CIMP), which defines cancers with a high
degree of CpG island methylation, in combination with
extremely low mutation levels and no somatic single-
nucleotide variants [10]. The characteristics of ependy-
momas support the model that epigenetic aberrations
can occur without any preceding genetic mutations.
These epigenetic aberrations are likely to be created
owing to modified external signals. Aberrant epigenetic
patterns are also found in many non-cancer diseases,
where the environment and external signals are major
contributors to the disease. Therefore, knowledge of
how external signals at different levels affect the DNA
methylation pattern is crucial to understand the devel-
opment of the affected disease, including AML.
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The cross-talk between transcription factors, such as
STAT6, and regulators of DNA methylation, such as
TET2, facilitates a greater control of transcriptional
regulation and stability of cell identity than would be
possible if each acted separately. Vento-Tormo and col-
leagues demonstrate how external signaling mediated by
IL-4 contributes to these interactions, which in turn
regulate DC differentiation. The instructing role of cyto-
kines in hematopoiesis is well established, but the authors
have demonstrated the detailed molecular interplay be-
tween cytokine signaling pathways and epigenetic mecha-
nisms, which has not previously been shown.
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